← Leaderboards
Patrick Hwu
Clinical Sciences
$17,535,407
Attributed
$20,531,886
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,946,752 · 16
By mechanism
R01$12,300,731 · 6
P01$11,837,776 · 3
P50$7,548,577 · 5
R21$256,668 · 1
R13$3,000 · 1
Top collaborators
- Michael Davies7 shared
- Gregory A Lizee4 shared
- James J Mule4 shared
- Laszlo George Radvanyi1 shared
Most similar at Clinical Sciences
Same institution · by research overlap
- David L Bartlett$7,205,000
- Nicholas P Restifo$0
- Larry W Kwak$10,852,773
- Crystal L Mackall$137,564
- Steven A Rosenberg$0
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaTumorT-LymphocyteImmuneMediatingMalignant NeoplasmsSiteCellsResponseImmunotherapyAntigensIn VivoImmune ResponseDendritic CellsMetastatic MelanomaClinical TrialsTumor AntigensNeoplastic CellCancer PatientDesignImmune SystemMolecularAntitumor ResponseLead
Grant awards (73)
Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer$581,244
R01 · FY2025 · CA
Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer$552,182
R01 · FY2024 · CA
Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer$569,619
R01 · FY2023 · CA
Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer$596,742
R01 · FY2022 · CA
Administrative Core 1$228,478
P50 · FY2021 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Melanoma$2,083,190
P50 · FY2019 · CA · contact PI
Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.$346,624
P50 · FY2019 · CA · contact PI
Project 2 Intrathecal Anti-PD-1 Immunotherapy for Metastatic Melanoma Patients with Leptomeningeal Disease (LMD)$311,515
P50 · FY2019 · CA · contact PI
Administrative Core 1$244,854
P50 · FY2019 · CA · contact PI
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy$340,821
R01 · FY2018 · CA · contact PI
The role of the PI3K pathway in immune resistance$332,000
R01 · FY2018 · CA · contact PI
The role of the PI3K pathway in immune resistance$160,000
R01 · FY2018 · CA · contact PI
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy$337,982
R01 · FY2017 · CA · contact PI
The role of the PI3K pathway in immune resistance$332,000
R01 · FY2017 · CA · contact PI
The role of the PI3K pathway in immune resistance$160,000
R01 · FY2017 · CA · contact PI
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy$337,726
R01 · FY2016 · CA · contact PI
The role of the PI3K pathway in immune resistance$332,000
R01 · FY2016 · CA · contact PI
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy$340,821
R01 · FY2015 · CA · contact PI
The role of the PI3K pathway in immune resistance$332,000
R01 · FY2015 · CA · contact PI
Induction of an Antitumor Immune Response in Patients with Melanoma$998,246
P50 · FY2014 · CA · contact PI
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy$355,821
R01 · FY2014 · CA · contact PI
The role of the PI3K pathway in immune resistance$332,000
R01 · FY2014 · CA · contact PI
Transduction of T cells to improve migration to tumor$264,095
R01 · FY2014 · CA · contact PI
Transduction of T cells to improve migration to tumor$323,570
R01 · FY2013 · CA · contact PI
Induction of an Antitumor Immune Response in Patients with Melanoma$169,328
P50 · FY2013 · CA · contact PI
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity$1,898,043
P01 · FY2012 · CA · contact PI
Induction of an Antitumor Immune Response in Patients with Melanoma$1,153,528
P50 · FY2012 · CA · contact PI
Clinical Trail of Vaccine in Combination with Toll-Like Receptor (TLR)$386,857
P01 · FY2012 · CA · contact PI
Transduction of T cells to improve migration to tumor$335,525
R01 · FY2012 · CA · contact PI
Administrative Core$133,973
P01 · FY2012 · CA · contact PI
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity$2,017,261
P01 · FY2011 · CA · contact PI
Induction of an Antitumor Immune Response in Patients with Melanoma$999,555
P50 · FY2011 · CA · contact PI
Transduction of T cells to improve migration to tumor$500,533
R01 · FY2011 · CA · contact PI
Clinical Trail of Vaccine in Combination with Toll-Like Receptor (TLR)$466,156
P01 · FY2011 · CA · contact PI
Administrative Core$142,254
P01 · FY2011 · CA · contact PI
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity$76,630
P01 · FY2011 · CA · contact PI
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity$1,837,241
P01 · FY2010 · CA · contact PI
Induction of an Antitumor Immune Response in Patients with Melanoma$1,013,259
P50 · FY2010 · CA · contact PI
Clinical Trail of Vaccine in Combination with Toll-Like Receptor (TLR)$442,258
P01 · FY2010 · CA · contact PI
Transduction of T cells to improve migration to tumor$353,855
R01 · FY2010 · CA · contact PI
DC Vaccination to Enhance Adoptive T Cell Transfer$260,253
R01 · FY2010 · CA · contact PI
Plasmacytoid DC Interactions in the Generation of an Antitumor Immune Response$258,529
R01 · FY2010 · CA · contact PI
Administrative Core$149,472
P01 · FY2010 · CA · contact PI
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity$79,000
P01 · FY2010 · CA · contact PI
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity$1,752,897
P01 · FY2009 · CA · contact PI
Clinical Trail of Vaccine in Combination with Toll-Like Receptor (TLR)$345,281
P01 · FY2009 · CA · contact PI
DC Vaccination to Enhance Adoptive T Cell Transfer$332,740
R01 · FY2009 · CA · contact PI
Transduction of T-cells to improve migration to tumor$282,772
R01 · FY2009 · CA · contact PI
Plasmacytoid DC Interactions in the Generation of an Antitumor Immune Response$264,073
R01 · FY2009 · CA · contact PI
DC Vaccination to Enhance Adoptive T Cell Transfer$260,253
R01 · FY2009 · CA · contact PI
Administrative Core$144,048
P01 · FY2009 · CA · contact PI
DC Vaccination to Enhance Adoptive T Cell Transfer$57,908
R01 · FY2009 · CA · contact PI
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity$1,670,604
P01 · FY2008 · CA · contact PI
Transduction of T-cells to improve migration to tumor$282,772
R01 · FY2008 · CA · contact PI
Plasmacytoid DC Interactions in the Generation of an Antitumor Immune Response$264,073
R01 · FY2008 · CA · contact PI
DC Vaccination to Enhance Adoptive T Cell Transfer$260,253
R01 · FY2008 · CA · contact PI
Clinical Trail of Vaccine in Combination with Toll-Like Receptor (TLR)$202,647
P01 · FY2008 · CA · contact PI
Administrative Core$93,154
P01 · FY2008 · CA · contact PI
DC Vaccination to Enhance Adoptive T Cell Transfer$56,400
R01 · FY2008 · CA · contact PI
Transduction of T-cells to improve migration to tumor$282,772
R01 · FY2007 · CA · contact PI
DC Vaccination to Enhance Adoptive T Cell Transfer$260,253
R01 · FY2007 · CA · contact PI
Plasmacytoid DC Interactions in the Generation of an Antitumor Immune Response$258,529
R01 · FY2007 · CA · contact PI
DC Vaccination to Enhance Adoptive T Cell Transfer$24,898
R01 · FY2007 · CA · contact PI
Transduction of T-cells to improve migration to tumor$291,217
R01 · FY2006 · CA · contact PI
DC Vaccination to Enhance Adoptive T Cell Transfer$268,025
R01 · FY2006 · CA · contact PI
Plasmacytoid DC Interactions in the Generation of an Antitumor Immune Response$266,250
R01 · FY2006 · CA · contact PI
Immunotherapy of tumor with A Novel Cytokine IL-21$126,808
R21 · FY2006 · CA · contact PI
Transduction of T-cells to improve migration to tumor$298,225
R01 · FY2005 · CA
Immunotherapy of tumor with A Novel Cytokine IL-21$129,860
R21 · FY2005 · CA
Advances in the Understanding and Treatment of Melanoma$3,000
R13 · FY2005 · CA
Improving the Function of Tumor-Reactive T-cells$0
Z01 · FY2002 · SC
The Genetic Modification of Hematopoietic Cells for Canc$0
Z01 · FY2001 · SC
The Genetic Modification of Hematopoietic Cells for Cancer Therapy$0
Z01 · FY2000 · SC